Microspheres as a novel drug delivery sysytem - A review

International Journal of ChemTech Research

Volumn 1, Issue 3, 2009, Pages 526-534

  Alagusundaram, M ^a   Madhu Sudana Chetty, C ^a   Umashankari, K ^a   Badarinath, Attuluri Venkata ^a   Lavanya, C ^a   Ramkanth, S ^a  

^a ANNAMACHARYA COLLEGE OF PHARMACY   (India)

Author keywords

Controlled release; Microspheres; Novel drug delivery; Specificity; Target site; Therapeutic efficacy

Indexed keywords

AGAROSE; ALBUMIN; ANTINEOPLASTIC AGENT; CARBOXYLIC ACID; CARRAGEENAN; CHITOSAN; COLLAGEN; DEFEROXAMINE; DEXTRAN; EDETIC ACID; GELATIN; MICROSPHERE; MONOCLONAL ANTIBODY; PENTETIC ACID; POLYMER; RADIOPHARMACEUTICAL AGENT; STARCH; VACCINE;

BIOCOMPATIBILITY; CHEMICAL MODIFICATION; CHEMOEMBOLIZATION; CONTACT ANGLE; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG TARGETING; EMULSION; ISOELECTRIC POINT; NONHUMAN; PARTICLE SIZE; PHASE SEPARATION; PHYSICAL CHEMISTRY; POLYMERIZATION; REVIEW; SOLVENT EXTRACTION; SPRAY DRYING; SUSTAINED RELEASE FORMULATION;

EID: 77953462836     PISSN: None     EISSN: 09744290     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. N.K.Jain, Controlled and Novel drug delivery, 04 Edition, 236-237, 21.
2. S.P.Vyas and R.K.Khar, Targeted and Controlled drug delivery, 07 Edition, 418.
3. Kreuter J., Nefzger M., Liehl E., CzokR. and Voges R. (1983) J.Pharm sci.72, 1146.
4. Margel S. and Wiesel E. (1984) J.polym.sci.22, 145.
5. Wakiyama N., Juni K. and Nakano M.(1981) chem..pharm.Bull.29, 3363.
6. Sugibayashi K., Akimoto M., Moromoto Y., Nadai T. and Kato Y.(1979) pharmacobiodyn.23,50.
7. Yoshioka T., Hashida M., Muranishi S. and SezakiH. (1981) Int.J.pharm. 8,131.
8. Russel G.F. (1983) pharma.Int.4, 260.
9. Woodland J.H.R., Yolles S., Blake D.A., Hetrich M.and Meyer F.J.(1973) J. Med.chem.16,897.
10. Rojas J., Pinto. Alphandary H., LeoE., Pecqests., couvreur P., Gulik A. and Fattal. E. (1999) Pharm Res.16, 255.
11. Albertson AC., Carlfors J. and Sturess on C. (1993) J. Appl.polym.Sci.62, 695.
12. Renbaum A. (1983) US patent 4,413,070.
13. S.P.Vyas & R.K.Khar, Targeted & Controlled drug delivery. 2007 Edition, 435.
14. Koff US patent (March21963) 3,080,292.
15. John P.M and Becker. C.H. (1968) J.pharm. sci.57, 584.
16. Schugens C., Larvelle. N., Nihantn., Grandfils C., Jerome R. and Teyssie. P. (1994) J.Control.Rel.32,161.
17. Mathews B.R. and Nixon J.R.(1974)J.pharm Pharmacrol.26,283.
18. N.K.Jain, Advances in controlled & Novel drug delivery, 03 Edition, 71.
19. Venkatesh H. (1989) "A buccal delivery system of Salbutamol Sulphate" M.Pharm; Budrinarayan, N. (1991) "Utilisation and Evaluation of plant products in pharmaceutical formulations".M.Pharm.
20. Tanaka, W; Akito, E; Yoshida, K.; Terada, T.and Ninomiya, H. (1977) "pharmaceutical preparations for oral cavity administration" US patent No.4059686.
21. Ishida, M; Nambu, N.and Nagai, T. (1983a) "Highly viscous gel ointment containing carbapol for application to the oral mucosa". Chem..pharm Bull., 31:4561.
22. Collins, A.E and Deasy, P.B (1990) "Bioadhesive lozenge for the improved delivery of cetypyridinium chloride".J.pharm.sci., 79(2):116-120.
23. Save T. and Venkatachalam P. (1994) "Bioadhesive tablets of Nifedipine: Standardization of a novel buccoadhesive erodible carrier". Drug Dev.Ind. pharm., 20(19): 3005-3014.
24. th Int.Symp. Control.Rel.Bioact.Mater., 650.
25. Lopez, C.R; Portero, A.; Vila-Jato, J.C. and Alonso, M.J. (1998) "Design and Evaluation of Chitosan/Ethylcellulose mucoadhesive bilayered devices for buccal drug delivery."J.control.Rel., 55: 143-152.
26. Parodi, B.; Russo, E.; Caviglioli, G.; Cafaggi, S.and Binardi, G. (1996) "Development &characterization of a buccoadhesive dosage from of Oxydodone hydrochloride". Drug Dev.Ind.pharm., 22(5):445-450.
27. Chien, Y.W.; Corbo, D.C. and Liv, J.C. (1991) "Mucosal delivery of progestational Steroids from a Controlled release device: in vitro/in vivo relationship."Drug Dev.Ind.pharm., 17(17):2269-2290.
28. Cassidy, J.P.; Landcert, N.M.and Quardos, E. (1993) "controlled buccal delivery of buprenorphine". J.control .Rel., 25: 21-29.
29. Dortune, B.; Ozer, L.and Vyanik, N.(1998) "Development and invitro Evaluation of buccoadhesive pindodlo tablet formulation." Drug Dev.Ind.pharm., 24(3):281-288.
30. Guo, J.H. (1994) "Bioadhesive polymer buccal patches for buprenorphine controlled delivery: formulation in vitro adhesive and release properties". Drug Dev.Ind.pharm., 20(3):315-325.
31. Nagai, T.; Machida, Y.; Suzuki Y.and Ikura, H. (1980) "Method & preparation for administration to the mucosa & preparation for administration to the mucosa of the oral or nasal cavity" US patent NO.4226848.
32. Chein, Y.W.and Novir, M. (1996) "Mucosal adhesive device for long acting delivery of pharmaceutical combinations in oral cavity". US patent NO.5578315.
33. Fabregas, J.L.and Garcia, N. (1995) "Invitro studies on buccoadhesive tablet formulations of hydro cortisone hemisuccinate". Drug Dev.Ind.pharm., 21(14): 1689-1696.
34. Rathbone, M.J.; Purve, R.: Ghazati, F.A.and HO, P.C. (1996) "In vivo techniques for studying the oral mucosa absorption characteristics of drugs in animals and humans." In Rathbone, M.J. (ed.), oral mucosal delivery systems, Marcel Dekker Inc.Newyork., 121-156.
35. Lu, M.F.and Hui, H.W. (1996) "Delivery of rennin inhibitors through mouth mucosa". Drug Dev.Ind.pharm., 22 (11); 1167-1171.
36. Yukimatsu, K.; Nozaki, Y.; Kakumoto, M.and Ohta, M. (1994) "Development of a transmucosal controlled release device for systemic delivery of antianginal drugs pharmacokinetics and pharmacodynamics". Drug Dev.Ind.pharm, 20(4): 503-534.
37. Hussain, M.A; Aungst, B.J.; Kearney A. and Shefter, E. (1987) "Buccal and oral bioavailability of naloxone and naltrexone in rats". INT, J.pharm., 36:127.
38. Oh, C.K. and Ritschel., W.A. (1999a) "Biopharmaceutical aspects of buccal absorption of insulin rabbits I. Effects of dose, size, Ph & sorption enhancers: in vivo in vitro correlation". Pharm.Res., 5-5-100.
39. Oh, C.K. and Ritschel, W.A. (1988b) "Biopharmaceutical aspects of buccal absorption of insulin in rabbits II. Absorption characteristics of insulin through the buccal mucosa". pharma.Res.,5-5-100.
40. Kellaway, I.W. and warren, S.I. (1991) "Mucoadhesive hydrogels". Proc.Intern.symp.Control.Rel.Bioact.Mater., 18:73.
41. Ishida, M.: Nambu, N.and Nagai, T.(1983a) "Highly viscous gel ointment containing carbopol for application to the oral mucosa".Chem. pharm.Bull., 31:4561.
42. Ishida, M.; Nambu, N. and Nagai, T. (1983b) "Ointment type oral mucosal dosage form of carbopol containing prednisolone for the treatment of aphtha". Chem.pharm.Bull., 31:1010.
43. Hoogstrate, A.J., verhoef, J.C.; Tuk., B.;Pijpers, A.; Vercheijden,J.H.M.; Jungiger, H.E. and Bodde, H.C. (1996b) "Invivo buccal delivery of fluorescein iso thiocyanate - dextran 4400 with glycodeoxy cholate as an absorption enhacer in pigs". J.pharm.sci., 85(5): 457-460.
44. Burnside, B.A; Keith, A.P. and snipes, W.(1989) "micro porous hollow fibers as a peptide delivery system via the buccal activity".proceed. inter.symp.control.Rel.Bioact. mater.,16:94.
45. Rathone, M.J. (1991a) "Human buccal absorption I.A method for Estimating the transfer kinetics of drugs W cross the human buccal membrane". Int.J.pharm., 69:103.
46. N.Venkateswarlu, Biopharmaceutics and kinetics, 2004 Edition, 53, 54.
47. Widder K.J., Sanyci A.E., Ovadia H., and Paterson P.Q. (1979) Clin.Immuno.Immuno pathol.14.395.
48. Funden berg H.H., Stites D.P., Caldwel J.L.and Wells J.V. (1978) In: Basic and clinical immunology, 2 ed., Lange Medical, Los Altosca.
49. Capron A.C., Locht C. and Fracchia G.N (1994) Vaccine.12, 667; Edelman R. (1993) vaccine 11, 1361; Drews J. (1984) Immunostimulantien, Klin. Wochenscher.62, 254; Spier K.E. (1993) vaccine 11, 1450.
50. Nachts S. and Martin K. (1990) In: The microsponges a novel topical programmable delivery formulation, Marcel Dekker Inc., Newyork., 299.